Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zephyrus II pamrevlumab trial in idiopathic pulmonary fibrosis
NL-OMON54236Phase 3Completed
- Sponsor
- FibroGen
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pamrevlumab in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by FibroGen. Primary endpoint: Change in forced vital capacity from baseline at Week 48. Started Mar 2022; status: completed.
02
Drugs
pamrevlumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON54236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54236.